Nyxoah SA (NYXH)
9.39
+0.22
(+2.40%)
USD |
NASDAQ |
May 31, 16:00
9.31
-0.08
(-0.85%)
After-Hours: 20:00
Nyxoah Revenue (Quarterly): 1.326M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.326M |
| December 31, 2023 | 1.964M |
| September 30, 2023 | 1.063M |
| June 30, 2023 | 1.207M |
| March 31, 2023 | 0.4737M |
| December 31, 2022 | 1.336M |
| September 30, 2022 | 0.1833M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.997M |
| March 31, 2022 | 0.7406M |
| December 31, 2021 | 0.3374M |
| September 30, 2021 | 0.2393M |
| June 30, 2021 | 0.2049M |
| March 31, 2021 | 0.2229M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.1833M
Minimum
Sep 2022
1.964M
Maximum
Dec 2023
0.792M
Average
0.7406M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Galapagos NV | 67.81M |
| UCB SA | -- |
| Mithra Pharmaceuticals SA | -- |
| Celyad Oncology SA | -- |
| MDxHealth SA | 19.83M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -12.93M |
| Total Expenses (Quarterly) | 14.59M |
| EPS Diluted (Quarterly) | -0.4508 |
| Enterprise Value | 231.17M |
| Gross Profit Margin (Quarterly) | 62.74% |
| Profit Margin (Quarterly) | -975.1% |
| Earnings Yield | -17.42% |
| Normalized Earnings Yield | -17.28 |